X-ZELL selected for prestigious accelerator program
Singapore, July 2020 – X-ZELL is one of 20 start-ups to be selected for MedTech Innovator’s 2020 Asia Pacific Accelerator program.
Founded in 2013, MedTech Innovator is a Los Angeles-based non-profit organisation specialising in medical technology and digital health, with a mandate to identify the most promising start-ups across both the United States and Asia.
Organised in partnership with the Asia Pacific Medical Technology Association (APACMed) and sponsored by Johnson & Johnson Medical Devices, the company’s accelerator program was designed to support the region’s “best and brightest” on the road to bringing innovative ideas to market.
“MedTech Innovator’s program companies represent the best of the best, and we are thrilled to announce the 20 start-ups carefully selected to participate in this year’s Asia Pacific program,” said Paul Grand, CEO of MedTech Innovator.
“These promising start-ups are committed to addressing health issues that are prevalent in the Asia Pacific region with the goal of improving the lives of patients through leading-edge innovation.”
According to Grand, more than 170 companies applied for the Asia Pacific part of the program, which will culminate in a high-profile showcase at the Asia Pacific MedTech Forum in Singapore, to be held from 26-28 April 2021.
As part of the showcase, the 20 finalists will have the opportunity to present to an audience of more than 750 delegates, including health care industry leaders, health care providers, and investors from across the region.
Four companies will then proceed to the Grand Final and have a chance to win a non-dilutive cash prize as well as the title of “2020 MedTech Innovator Asia Pacific Winner”.
For more information on the 2020 accelerator program, click here.
Head of Strategy, Marketing & Communications
+65 9630 0706
X-ZELL’s vision is to save lives by identifying clinically significant cancers early, when there is still time to act and take charge of our health. X-ZELL first made headlines in 2017 when it found a way to routinely locate tumour-associated Circulating Endothelial Cells (tCEC) in a small, 10mL blood sample. Known to be powerful biomarkers for the early detection of aggressive cancers, tCEC were long considered ‘undetectable’ in clinical routine. X-ZELL overcame the impasse by developing a platform technology that is capable of detecting a single tCEC among five billion healthy blood cells and analysing it using Artificial Intelligence – making for an affordable, non-invasive solution with maximum scalability. Less than a year after that breakthrough, X-ZELL was able to present the world’s first tCEC-based blood test for the early detection of clinically significant prostate cancer – X-ZELL™ Prostate. But one cancer is not enough. X-ZELL’s ambition is to make accurate, affordable tCEC screening available to everyone, everywhere – which is why additional tests for common cancers such as breast, ovarian, colon and lung have already gone into pre-development, with more to come. They all feed into the creation of an AI-driven general screening test that will be able to scrutinise our blood for atypical cells and analyse them on-screen – allowing physicians to manage our health proactively instead of just responding to a disease.
About MedTech Innovator
Founded in 2013, MedTech Innovator is a Los Angeles-based non-profit organisation specialising in medical technology and digital health, with a mandate to identify the most promising start-ups across both the United States and Asia. The company’s mission is “to improve the lives of patients by matching healthcare industry leaders with innovative early-stage med tech companies for mentorship and support”.
© 2023 X-ZELL INC